Tormohlen Kayla N, Bicket Mark C, White Sarah, Barry Colleen L, Stuart Elizabeth A, Rutkow Lainie, McGinty Emma E
624 N. Broadway, Room 357, Baltimore, MD 21205.
1500 E Medical Center Drive, Ann Arbor, MI 48109-5048.
Curr Addict Rep. 2021 Dec;8(4):538-545. doi: 10.1007/s40429-021-00397-1. Epub 2021 Sep 28.
This review summarizes studies examining impacts of medical and recreational cannabis laws on opioid prescribing, opioid use, opioid use disorder, opioid-related service utilization, and opioid-involved mortality. We also discuss research challenges and recommendations for future work.
Twenty-one U.S. based studies published between 2014-2021 that assessed state cannabis laws' association with opioid-related outcomes were reviewed. Study results were largely inconclusive. We identified six challenges of existing work: 1) inability to directly measure cannabis/opioid substitution; 2) use of general population samples and lack of individual-level longitudinal studies; 3) challenges disentangling effects of cannabis laws from other state laws; 4) methodological challenges with staggered policy implementation; 5) limited consideration of cannabis law provisions; 6) lack of triangulation across data sources.
While existing research suggests the potential for cannabis laws to reduce high-risk opioid prescribing and other opioid-related adverse outcomes, studies should be interpreted in light of limitations.
本综述总结了研究医用大麻和消遣用大麻法律对阿片类药物处方、阿片类药物使用、阿片类药物使用障碍、阿片类药物相关服务利用以及阿片类药物相关死亡率影响的研究。我们还讨论了研究挑战以及对未来工作的建议。
对2014年至2021年间发表的21项基于美国的研究进行了综述,这些研究评估了州大麻法律与阿片类药物相关结果之间的关联。研究结果大多尚无定论。我们确定了现有工作的六个挑战:1)无法直接衡量大麻/阿片类药物替代情况;2)使用一般人群样本且缺乏个体层面的纵向研究;3)难以区分大麻法律与其他州法律的影响;4)政策实施交错带来的方法学挑战;5)对大麻法律条款的考虑有限;6)缺乏跨数据源的三角测量法。
虽然现有研究表明大麻法律有可能减少高风险阿片类药物处方及其他阿片类药物相关不良后果,但鉴于研究存在局限性,对这些研究结果应谨慎解读。